Literature DB >> 18097462

Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer.

Peter Karran1, Natalie Attard.   

Abstract

Thiopurines have diverse clinical applications and their long-term use as anti-rejection drugs in transplant patients has been associated with a significantly increased risk of various types of cancer. Although they are slowly being replaced by a new generation of non-thiopurine immunosuppressants, it is anticipated that their use in the management of inflammatory and autoimmune diseases will continue to increase. Therapy-related cancer will remain a potential consequence of prolonged treatment for these generally non-life-threatening conditions. Understanding how thiopurines contribute to the development of cancer will facilitate clinical decisions about the potential risks to patients of long-term treatment for chronic inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097462     DOI: 10.1038/nrc2292

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  151 in total

1.  AFB(1) -induced mutagenesis of the gpt gene in AS52 cells.

Authors:  Roongtiwa Wattanawaraporn; Min Young Kim; Jillian Adams; Laura J Trudel; Leslie L Woo; Robert G Croy; John M Essigmann; Gerald N Wogan
Journal:  Environ Mol Mutagen       Date:  2012-06-26       Impact factor: 3.216

2.  NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.

Authors:  Takaya Moriyama; Rina Nishii; Virginia Perez-Andreu; Wenjian Yang; Federico Antillon Klussmann; Xujie Zhao; Ting-Nien Lin; Keito Hoshitsuki; Jacob Nersting; Kentaro Kihira; Ute Hofmann; Yoshihiro Komada; Motohiro Kato; Robert McCorkle; Lie Li; Katsuyoshi Koh; Cesar Rolando Najera; Shirley Kow-Yin Kham; Tomoya Isobe; Zhiwei Chen; Edwynn Kean-Hui Chiew; Deepa Bhojwani; Cynthia Jeffries; Yan Lu; Matthias Schwab; Hiroto Inaba; Ching-Hon Pui; Mary V Relling; Atsushi Manabe; Hiroki Hori; Kjeld Schmiegelow; Allen E J Yeoh; William E Evans; Jun J Yang
Journal:  Nat Genet       Date:  2016-02-15       Impact factor: 38.330

3.  Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis.

Authors:  Kevin Zarca; Isabelle Durand-Zaleski; Marie-Anne Loriot; Gilles Chatellier; Nicolas Pallet
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

4.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.

Authors:  Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Journal:  Cell Discov       Date:  2020-03-16       Impact factor: 10.849

5.  DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.

Authors:  Hee Young Ju; Ji Won Lee; Hee Won Cho; Ju Kyung Hyun; Youngeun Ma; Eun Sang Yi; Keon Hee Yoo; Ki Woong Sung; Rihwa Choi; Hong Hoe Koo; Soo-Youn Lee
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

6.  Structures of a DNA Polymerase Inserting Therapeutic Nucleotide Analogues.

Authors:  Matthew A Schaich; Mallory R Smith; Ashley S Cloud; Sean M Holloran; Bret D Freudenthal
Journal:  Chem Res Toxicol       Date:  2017-09-01       Impact factor: 3.739

7.  Protein oxidation and DNA repair inhibition by 6-thioguanine and UVA radiation.

Authors:  Quentin Gueranger; Feng Li; Matthew Peacock; Annabel Larnicol-Fery; Reto Brem; Peter Macpherson; Jean-Marc Egly; Peter Karran
Journal:  J Invest Dermatol       Date:  2013-11-27       Impact factor: 8.551

8.  mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.

Authors:  Thanh-Trang T Vo; J Scott Lee; Duc Nguyen; Brandon Lui; William Pandori; Andrew Khaw; Sharmila Mallya; Mengrou Lu; Markus Müschen; Marina Konopleva; David A Fruman
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

9.  Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity.

Authors:  Chase C Suiter; Takaya Moriyama; Kenneth A Matreyek; Wentao Yang; Emma Rose Scaletti; Rina Nishii; Wenjian Yang; Keito Hoshitsuki; Minu Singh; Amita Trehan; Chris Parish; Colton Smith; Lie Li; Deepa Bhojwani; Liz Y P Yuen; Chi-Kong Li; Chak-Ho Li; Yung-Li Yang; Gareth J Walker; James R Goodhand; Nicholas A Kennedy; Federico Antillon Klussmann; Smita Bhatia; Mary V Relling; Motohiro Kato; Hiroki Hori; Prateek Bhatia; Tariq Ahmad; Allen E J Yeoh; Pål Stenmark; Douglas M Fowler; Jun J Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-24       Impact factor: 11.205

10.  Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Authors:  K Schmiegelow; E Forestier; J Kristinsson; S Söderhäll; K Vettenranta; R Weinshilboum; F Wesenberg
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.